Clinicians looking for comprehensive sickle cell anemia resources need three things in one place: the core biology, the screening and monitoring schedule, and a clear plan for acute complications. This page brings those together as a practical reference, drawing on well-established recommendations from bodies such as the US National Heart, Lung, and Blood Institute (NHLBI) and the American Society of Hematology (ASH). It is a summary for orientation, not a substitute for your local protocols.
Core Pathophysiology in Brief
Sickle cell anemia (HbSS) is an autosomal recessive disorder caused by a single nucleotide substitution in the HBB gene. The change replaces glutamic acid with valine at position 6 of the beta-globin chain, producing hemoglobin S (HbS).
When deoxygenated, HbS polymerizes into long fibers that distort the red cell into a rigid sickle shape. These cells damage the endothelium, adhere to vessel walls, and lyse early. Normal function of red blood cells depends on flexibility and a lifespan of about 120 days; sickle cells often survive only 10 to 20 days.
The result is two intertwined processes: chronic hemolytic anemia and vaso-occlusion. Together they explain nearly every acute and chronic complication.
Genotypes you will encounter
| Genotype | Description | Typical clinical severity |
|---|---|---|
| HbSS | Two sickle alleles (sickle cell anemia) | Usually severe |
| HbS/beta-zero thalassemia | Sickle allele plus a beta-thalassemia allele with no beta-globin output | Usually severe, similar to HbSS |
| HbSC | Sickle allele plus hemoglobin C allele | Often milder anemia; retinopathy and bone complications still important |
| HbS/beta-plus thalassemia | Sickle allele plus a beta-thalassemia allele with reduced output | Generally milder |
| HbAS (sickle cell trait) | One sickle allele; carrier state | Usually asymptomatic; rare risks with extreme exertion and dehydration |
Diagnosis and Screening
In countries with universal newborn screening, most cases are identified at birth. Confirmation uses hemoglobin electrophoresis, high-performance liquid chromatography (HPLC), or isoelectric focusing, with DNA testing when results are ambiguous.
- CBC and reticulocyte count: baseline hemoglobin in HbSS is commonly around 6 to 9 g/dL, with a raised reticulocyte count.
- Blood film: sickle cells, target cells, and, after the spleen stops working, Howell-Jolly bodies.
- Hemolysis markers: raised indirect bilirubin and lactate dehydrogenase, low haptoglobin.
- Extended red cell antigen typing: recommended before first transfusion to reduce alloimmunization.
Knowing each patient’s steady-state hemoglobin and reticulocyte count is essential. Acute changes are judged against that baseline, not against the normal reference range.
Preventive Care Checklist
Much of the improvement in childhood survival has come from simple preventive measures. The table below summarizes widely accepted elements; exact ages and intervals follow your national guidance.
| Measure | Who and when | Purpose |
|---|---|---|
| Oral penicillin prophylaxis | HbSS and HbS/beta-zero children from diagnosis until at least age 5 | Prevent invasive pneumococcal infection due to functional asplenia |
| Pneumococcal and routine vaccines | All patients, per schedule; annual influenza vaccine | Reduce infection risk |
| Transcranial Doppler (TCD) | Children with HbSS or HbS/beta-zero, yearly from about age 2 to 16 | Identify high stroke risk; abnormal results prompt chronic transfusion |
| Hydroxyurea | Offered to children from 9 months and to adults with HbSS or HbS/beta-zero | Raises fetal hemoglobin, reduces pain crises and acute chest syndrome |
| Retinal screening | Dilated eye exam starting around age 10 | Detect proliferative retinopathy, especially in HbSC |
| Kidney and blood pressure checks | Annual urine protein screening from about age 10; regular BP | Detect sickle nephropathy early |
| Folic acid | Commonly prescribed | Support increased red cell production |
Family education matters as much as any test. Parents should know how to palpate the spleen, recognize fever as an emergency, and when to go straight to hospital.
Recognizing and Managing Acute Complications
Vaso-occlusive pain crisis
The most common reason for hospital visits. Treat pain rapidly, ideally within an hour of arrival, using opioids when needed and an individualized pain plan. Encourage hydration, avoid over-hydration, and use incentive spirometry to lower the risk of acute chest syndrome.
Acute chest syndrome
Defined as a new infiltrate on chest imaging plus fever and/or respiratory symptoms such as cough, chest pain, or hypoxia. Management includes oxygen, antibiotics covering atypical organisms, analgesia, and transfusion (simple or exchange) for worsening cases. It is a leading cause of death, so early escalation is key.
Other emergencies
- Fever of 38.5°C or higher: urgent assessment, blood cultures, and prompt parenteral antibiotics.
- Acute stroke: urgent imaging and exchange transfusion.
- Splenic sequestration: sudden enlargement of the spleen with a falling hemoglobin, mainly in young children.
- Aplastic crisis: falling hemoglobin with a very low reticulocyte count, classically after parvovirus B19 infection.
- Priapism: a urological emergency if prolonged.
Disease-Modifying and Curative Therapies
Hydroxyurea remains the backbone of disease modification. Other options include chronic transfusion programs for stroke prevention and L-glutamine in some settings.
Allogeneic hematopoietic stem cell transplantation, especially from a matched sibling donor, can cure the disease and is considered for patients with severe complications. In recent years, gene therapies, including a CRISPR-based therapy that reactivates fetal hemoglobin, have gained regulatory approval for selected patients with severe disease. Access, cost, and eligibility remain important limitations.
Special Populations and Transition
Children need tailored care, from spleen checks to school planning, which we cover in our article on sickle cell anemia in pediatric patients. Pregnancy carries higher risk of pain crises, thrombosis, and pre-eclampsia and should be co-managed with a high-risk obstetric team.
The move from pediatric to adult services is a known point of vulnerability. A planned transition, with the young person learning to manage their own medicines and appointments, reduces gaps in care. For patient-facing background, point families to our sickle cell guide.
Key Takeaways
- HbS polymerization drives both hemolysis and vaso-occlusion.
- Penicillin prophylaxis, vaccination, and TCD screening prevent much early mortality and stroke.
- Offer hydroxyurea early to eligible patients.
- Treat fever and acute chest syndrome as emergencies.
- Transplant and gene therapy offer cure for selected patients.
Frequently Asked Questions
At what age should hydroxyurea be started?
Current guidance supports offering hydroxyurea to infants with HbSS or HbS/beta-zero thalassemia from 9 months of age, regardless of symptoms. Adults with frequent pain or acute chest syndrome should also be offered it.
Why do patients with sickle cell disease need penicillin?
Repeated splenic infarction leads to functional asplenia early in childhood. This leaves children highly vulnerable to encapsulated bacteria such as pneumococcus, so daily penicillin is given through at least age 5.
Does sickle cell trait cause disease?
Carriers are usually healthy. Rare problems include blood in the urine, a small risk of complications with extreme exertion or dehydration, and a rare kidney cancer called renal medullary carcinoma.
How is an abnormal transcranial Doppler managed?
An abnormal result, typically a time-averaged mean velocity of 200 cm/s or higher, indicates high stroke risk. Standard practice is to start a chronic transfusion program, which substantially lowers first-stroke risk.
